Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

In the phase III SOLAR-1 trial (NCT02437318), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated, hormone recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciruelos, Eva Maria, Rugo, Hope S., Mayer, Ingrid A., Levy, Christelle, Forget, Frédéric, Delgado Mingorance, Juan Ignacio, Safra, Tamar, Masuda, Norikazu, Park, Yeon Hee, Juric, Dejan, Conte, Pierfranco, Campone, Mario, Loibl, Sibylle, Iwata, Hiroji, Zhou, Xiaolei, Park, Jinhee, Ridolfi, Antonia, Lorenzo, Ines, André, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210974/
https://www.ncbi.nlm.nih.gov/pubmed/33780274
http://dx.doi.org/10.1200/JCO.20.01139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210974/
https://www.ncbi.nlm.nih.gov/pubmed/33780274
http://dx.doi.org/10.1200/JCO.20.01139

Ejemplares similares